109181 ⎘
Structure or type of the nucleic acid; Chemical structure of the base; Modified C 5-Methylcytosine
Compositions and their uses directed to huntingtin
#902BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM
#903MODULATION OF TRANSTHYRETIN EXPRESSION
#904ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#905Reduced size self-delivering RNAi compounds
#906Targeting MicroRNAs For The Treatment Of Liver Cancer
#907RNA interference in skin indications
#908Neutral nanotransporters
#909Modulation of C-reactive protein expression
#910Oligomeric compounds for the modulation of HIF-1α expression
#911RNA ANTAGONISTS TARGETING HSP70-2
#912Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#913PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
#914ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION
#915Modulation of HIF1α and HIF2α expression
#916Potent LNA oligonucleotides for the inhibition of HIF-1A expression
#917METHODS FOR MODULATING EXPRESSION OF CREB
#918Conjugates For Use In Hepatocyte Free Uptake Assays
#919Complement antagonists and uses thereof
#920Modulation of glucose-6-phosphatase translocase expression
#921Modulation of CD40 expression
#922Bispecific oligonucleotide for the treatment of CNS malignancies
#923Modulation of SMRT expression
#924Methods for treating androgen receptor dependent disorders including cancers
#925RNA antagonists targeting Hsp27
#926RNA preparations comprising purified modified RNA for reprogramming cells
#927Compositions and their uses directed to acetyl-CoA carboxylases
#928Methods and compositions for the inhibition of gene expression
#929RNA ANTAGONISTS TARGETING GLI2
#930Methods for modulating expression of RBP4
#931Antisense modulation of C-reactive protein expression
#932Compositions and their uses directed to PTPRU
#933Compositions and their uses directed to gemin genes
#934Antisense formulation
#935ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION
#936Compounds for the modulation of beta-catenin expression
#937RNA antagonist compounds for the modulation of PIK3CA expression
#938Modulation of apolipoprotein C-III expression
#939MODULATION OF FACTOR 9 EXPRESSION
#940Method for reducing scarring during wound healing using antisense compounds directed to CTGF
#941Antisense oligonucleotide modulation of STAT3 expression
#942Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#943Modulation of apolipoprotein (a) expression
#944TRPM-2 antisense therapy
#945Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#946Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#947Methods and compositions for inhibition of immune responses and autoimmunity
#948EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS
#949Modulation of SGLT2 expression
#950RNA Antagonist Compounds for the Modulation of MCL-1
#951Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#952MODULATION OF HIF1 BETA EXPRESSION
#953Modulation of forkhead box O1A expression
#954Modulation of factor 7 expression
#955MicromiRs
#956Administering antisense oligonucleotides complementary to human apolipoprotein B
#957Antisense modulation of fibroblast growth factor receptor 4 expression
#958Combination treatment for the treatment of hepatitis C virus infection
#959Modulation of apolipoprotein (A) expression
#960Targeting microRNAs for the treatment of liver cancer
#961Method for inhibiting the activity of mir-155
#962SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA
#963Oligomeric compounds and compositions for use in modulation of pri-miRNAs
#964Antisense modulation of kinesin-like 1 expression
#965LNA antagonists targeting the androgen receptor
#966MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#967MODULATION OF GLUCOCORTICOID RECEPTOR EXPRESSION
#968Compositions and methods for modulation of SMN2 splicing
#969Short oligomer antagonist compounds for the modulation of target mRNA
#970Modulation of Stat 6 Expression for the Treatment of Airway Hyperresponsiveness
#971ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION
#972Antisense compounds
#973MODULATION OF SID-1 EXPRESSION
#974OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
#975Methods for treating hypercholesterolemia
#976Modulation of factor 11 expression
#977Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
#978Multiple exon skipping compositions for DMD
#979MODULATION OF eIF4E EXPRESSION
#980Methods for treating multiple sclerosis using antisense oligonucleotides
#981Modulation of HIF1-beta expression
#982Oligomeric compounds for the modulation of HIF-1alpha expression
#983METHODS FOR SLOWING FAMILIAL ALS DISEASE PROGRESSION
#984COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#985Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha
#986Novel tyrosinase-specific anti-gene oligonucleotides as depigmenting agents
#987Antisense modulation of connective tissue growth factor expression
#988Compositions and their uses directed to PTPR alpha
#989ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
#990Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#991Compositions and their uses directed to IL-4R alpha
#992CONJUGATED DOUBLE STRAND COMPOSITIONS FOR USE IN GENE MODULATION
#993Regulation of epigenetic control of gene expression
#994Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#995MODULATION OF STAT 6 EXPRESSION
#996Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#997Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#998Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
#999Potent LNA oligonucleotides for the inhibition of HIF-1a expression
#1000RNA containing modified nucleosides and methods of use thereof
#1001Modulation of insulin like growth factor I receptor expression
#1002Compositions and Their Uses Directed to IL-4R Alpha
#1003Antisense modulation of C-reactive protein expression
#1004MODULATION OF TUDOR-SN EXPRESSION
#1005HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF
#1006COMPOSITIONS AND THEIR USES DIRECTED TO HSP27
#1007MODULATION OF LMW-PTPASE EXPRESSION
#1008ANTISENSE COMPOUNDS HAVING ENHANCED ANTI-MICRORNA ACTIVITY
#1009Modulation of eIF4E-BP2 expression
#1010Compounds for the modulation of beta-catenin expression
#1011RNA antagonist compounds for the modulation of PIK3CA expression
#1012Modulation of eIF4E expression
#1013MODULATION OF STAT 6 EXPRESSION FOR THE TREATMENT OF AIRWAY HYPERRESPONSIVENESS
#1014Small internally segmented interfering RNA
#1015LNA antagonists targeting the androgen receptor
#1016LNA oligonucleotides and the treatment of cancer
#1017Modulation of C-reactive protein expression
#1018Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#1019MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
#1020MicroRNAs
#1021Antisense modulation of PTP1B expression
#1022RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
#1023MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION
#1024Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
#1025Modulation of diacylglycerol acyltransferase 1 expression
#1026Modulation of transthyretin expression
#1027Modulation of apolipoprotein (a) expression
#1028Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions
#1029Antisense oligonucleotides for prevention of metastasis formation of cancer cells
#1030COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
#1031RNA antagonist compounds for the modulation of HER3
#1032Isis Pharmaceuticals, Inc.
#1033Compositions and their uses directed to PTPRU
#1034Compositions and methods for the modulation of JNK proteins
#1035Modified Short Interfering Rna (Modified Sirna)
#1036Antisense modulation of apolipoprotein B expression
#1037Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#1038Antisense modulation of p38 mitogen activated protein kinase expression
#1039Oligomeric compounds for the modulation ras expression
#1040ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION
#1041Modulation of FR-alpha expression
#1042Treatment of neurological disorders by dsRNA administration
#1043Modulation of forkhead box O1A expression
#1044Antisense modulation of stearoyl-CoA desaturase expression
#1045Methods and compositions for the inhibition of gene expression
#1046Clusterin antisense therapy for treatment of cancer
#1047Compounds and Their Use for Specific and Simultaneous Inhibition of Genes Involved In Diseases and Related Drugs
#1048COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#1049TRPM-2 antisense therapy
#1050ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION
#1051Compositions and their uses directed to huntingtin
#1052Antisense modulation of kinesin-like 1 expression
#1053Immunostimulatory oligonucleotides
#1054BACKBONE MODIFICATIONS TO MODULATE OLIGONUCLEOTIDE TARGETING IN VIVO
#1055COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#1056Human RNase H1 oligonucleotide compositions thereof
#1057Compositions and their uses directed to hepcidin
#1058Compositions and methods for modulation of Mcl-1 expression
#1059MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 3 EXPRESSION
#1060Modulation of glucagon receptor expression
#1061MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#1062MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#1063MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#1064MODULATION OF ACE2 EXPRESSION
#1065Short interfering RNA (siRNA) analogues
#1066Modulation of ace2 expression
#1067Antisense IAP nucleobase oligomers and uses thereof
#1068Antisense oligonucleotides (ODN) against Smad7 and uses in medical field thereof
#1069COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#1070Compositions and their uses directed to IL-4R alpha
#1071Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
#1072Antisense IAP nucleobase oligomers and uses thereof
#1073Compositions and methods for the modulation of the expression of B7 protein
#1074Methods for slowing familial ALS disease progression
#1075Modulation of glucagon receptor expression
#1076Modulation of glucocorticoid receptor expression
#1077Aptamer medicinal chemistry
#1078Modulation of eIF4E expression
#1079Antisense modulation of superoxide dismutase 1, soluble expression
#1080Methods for use in modulating miR-122a
#1081Antisense modulation of fibroblast growth factor receptor 3 expression
#1082Antisense IAP nucleobase oligomers and uses thereof
#1083Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#1084Antisense IAP nucleobase oligomers and uses thereof
#1085Modulation of SOCS-3 expression
#1086Modulation of HIF1alpha and HIF2alpha expression
#1087Modulation of endothelial lipase expression
#1088Antisense modulation of superoxide dismutase 1, soluble expression
#1089Modulation of apolipoprotein (A) expression
#1090Modulation of apolipoprotein c-III expression
#1091Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
#1092Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
#1093Oligomeric compounds and compositions for use in modulation of pri-mirnas
#1094Potent LNA oligonucleotides for the inhibition of HIF-1A expression
#1095Modulation of HIF-1 beta expression
#1096Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
#1097Modulation of insulin like growth factor I receptor expression
#1098Methods and compositions for the inhibition of gene expression
#1099Antisense oligonucleotide modulation of STAT3 expression
#1100Immunostimulatory oligonucleotides
#1101Antisense modulation of farnesoid X receptor expression
#1102Methods and compositions for the inhibition of gene expression
#1103Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
#1104Antisense modulation of integrin beta 4 binding protein expression
#1105Modulation of glucocorticoid receptor expression
#1106Antisense modulation of CD40 ligand expression
#1107LNA oligonucleotides and the treatment of cancer
#1108Modulation of SLC26A2 expression
#1109Antisense oligonucleotide modulation of raf gene expression
#1110Methods and compositions for the inhibition of gene expression
#1111Use of mob-5 in pain
#1112Antisense modulation of vegf co-regulated chemokine-1 expression
#1113Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
#1114Conjugates for use in hepatocyte free uptake assays
#1115Antisense modulation of matrix metalloproteinase 1 expression
#1116Methods and compositions for the inhibition of gene expression
#1117Antisense modulation of hematopoietic cell protein tyrosine kinase expression
#1118Antisense oligonucleotides directed to genes regulated by trapoxin-induced HDAC inhibition
#1119Methods for modulating lipoprotein and cholesterol levels in humans
#1120Treatment of neurological disorders by dsrna administration
#1121Antisense modulation of c/ebp beta expression
#1122Modulation of glucocorticoid receptor expression
#1123Antisense modulation of PTP1B expression
#1124Antisense modulation of C-reactive protein expression
#1125Effects of apolipoprotein B inhibition on gene expression profiles in animals
#1126Bispecific oligonucleotide for the treatment of CNS malignancies
#1127Oligomeric compounds having modified phosphate groups
#1128Methods and compositions for the inhibition of gene expression
#1129SNPs of apolipoprotein B and modulation of their expression
#1130Modulation of growth hormone receptor expression and insulin-like growth factor expression
#1131Antisense modulation of ptpn12 expression
#1132Modulation of Aurora B expression
#1133Antisense modulation of p70 S6 kinase expression
#1134Modulation of glucose-6-phosphatase translocase expression
#1135Antisense modulation of interleukin 12 P35 subunit expression
#1136Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1137Modulation of pumilio 1 expression
#1138Modulation of Nanos 1 expression
#1139Antisense modulation of cellular apoptosis susceptibity gene expression
#1140Double stranded constructs comprising one or more short strands hybridized to a longer strand
#1141Modulation of transthyretin expression
#1142Sequence requirements for inhibitory oligonucleotides
#1143Modulation of STAT 6 expression
#1144Modulation of kallikrein 6 expression
#1145Antisense modulation of thyroid hormone receptor interactor 6 expression
#1146Methylenetetrahydrofolate reductase inhibitors and use thereof
#1147Antisense modulation of mucin 1, transmembrane expression
#1148Modulation of tyrosinase expression
#1149Antisense modulation of sterol regulatory element-binding protein-1 expression
#1150Compositions and their uses directed to signal transducers
#1151Antisense modulation of cellular inhibitor of Apoptosis-2 expression
#1152Antisense modulation of dual specific phosphatase 5 expression
#1153Modulation of SGLT2 expression
#1154Compositions and their uses directed to cell growth and maintenance proteins
#1155Antisense modulation of peroxisome proliferator-activated receptor gamma expression
#1156Antisense modulation of EIF2C1 expression
#1157Modulation of DC-SIGN expression
#1158Modulation of eIF4E-BP1 expression
#1159Antisense modulation of microsomal triglyceride transfer protein expression
#1160Chemically modified double stranded nucleic acid molecules
#1161Compositions and their uses directed to binding proteins
#1162Modulation of glucocorticoid receptor expression
#1163Methods of using mammalian RNase H and compositions thereof
#1164Human RNase III and compositions and uses thereof
#1165Compositions and their uses directed to transferases
#1166Antisense modulation of interferon gamma receptor 2
#1167Methods of using mammalian RNase H and compositions thereof
#1168Antisense modulation of extracellular-signal-regulated kinase-6 expression
#1169Human RNase H and compositions and uses thereof
#1170Compositions and their uses directed to nucleic acid binding proteins
#1171Modulation of RANKL expression
#1172Antisense modulation of survivin expression
#1173Antisense modulation of phospholipase A2, group IIA (synovial) expression
#1174Microrna as ligands and target molecules
#1175Antisense modulation of cholesteryl ester transfer protein expression
#1176Antisense inhibition via RNAse H-independent reduction in mRNA
#1177Compositions and their uses directed to signal tranducers
#1178Antisense oligonucleotides optimized for kidney targeting
#1179Antisense modulation of inducible nitric oxide synthase expression
#1180Antisense modulation of polo-like kinase expression
#1181Modulation of CEACAM1 expression
#1182Antisense modulation of PLML expression
#1183Antisense modulation of caspase 7 expression
#1184Antisense modulation of calreticulin expression
#1185Modulation of phosphodiesterase 4B expression
#1186Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
#1187Notch1 inhibitors for inducing apoptosis
#1188Antisense modulation of PTP1B expression
#1189Modulation of aminopeptidase N expression
#1190Antisense modulation of wrn espression
#1191Antisense oligonucleotide modulation of STAT3 expression
#1192Antisense modulation of ptpn2 expression
#1193Antisense modulation of acyl coenzyme a cholesterol acyltransferase-1 expression
#1194Mouse model for bone metabolism
#1195Antisense modulation of connective tissue growth factor expression
#1196Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
#1197Antisense modulation of insulin-like growth factor binding protein 5 expression
#1198Antisense modulation of stearoyl-CoA desaturase expression
#1199Phosphorous-linked oligomeric compounds and their use in gene modulation
#1200Modulation of the RNA interference pathway